18 October – VAXIMM: Hijacking bacteria to develop the next generation of cancer therapeutics

What will the future in cancer therapies hold? Next generations of cell therapies? Trispecific antibodies? Small molecule induced protein degradation? Or how about oral bacterial therapeutics? The biotech company VAXIMM believes the latter will play an important role in the journey towards finding curative cancer treatments. Their technology is based on first-in-class oral T-cell activators that can be readily adapted to target a wide range of cancer-related antigens, small peptides as well as full-length proteins. The company’s lead product, oral VXM01, completed a Phase I/II trial in advanced pancreatic cancer. In addition, the Company has several product candidates including neoantigen-targeting constructs at various stages of preclinical development. We are delighted to having Dr. Heinz Lubenau, COO and co-founder of VAXIMM, talking about the exciting story of the company’s lead product and promising trials and sharing lessons learned along the way.

Please join us at this event on October 18th 2018, 19:00 to 20:00, at Halle 7, Gundeldingerfeld, Dornacherstrasse 192, Basel.


18:45 Door opening
19:00 Introduction
19:05 Heinz Lubenau, COO VAXIMM
19:35 Q&A
20:00 Apero

Participation to the event is free of charge; however, your registration is mandatory. Register here.


Heinz Lubenau (*1965) is a Pharmacist whose work is focused on the field of Targeted Oral Immunotherapy Development. He is the Chief Operating Officer of the biotech VAXIMM since 2016, the company he co-founded in 2008. Heinz received his PhD from the Institute of Pharmacy, Johannes-Gutenberg-University, Mainz. From 1994 to 2002 Heinz held several important positions in Clinical Research at the pharmaceutical company Servier, moving from Junior Project Leader to Clinical Research Manager and Project Director of Internal Medicine. From 2003 to 2008 Heinz held the position of Global Project Manager Biosimilar and Head of Preclinical and Clinical Development at BioGenerix. Heinz is the owner of several patents and patent applications and has an impressive track record of marketed drugs.